GKOS Medical technology · Eye care · Medtech · Growth · Thesis updated June 14, 2026

iDose powers growth, but the price is steep

Q1 2026 net sales rose 41% year over year to $150.6 million, helped by a strong iDose TR launch.
U.S. Glaucoma sales were $93.5 million in Q1 2026, up 58% year over year, with $54 million from iDose TR.
Corneal Health grew 15% year over year to $21.3 million as Epioxa began its launch.
The company raised 2026 net sales guidance to $620 million to $635 million after Q1.
The main worry is still profit: Glaukos is growing fast, but costs are rising and the stock is not cheap.

01 Running thesis

A launch story with a high bar

Glaukos has become an iDose TR story. The product is a tiny implant that slowly releases glaucoma medicine inside the eye. In Q1 2026, it produced $54 million of sales and helped push total net sales up 41% year over year to $150.6 million.

The bull case is clear. iDose TR is scaling faster than the older stent business is fading. Epioxa, the newer corneal cross-linking product, also started well. Corneal Health grew 15% year over year in Q1 2026, even while Glaukos was moving doctors and payers from Photrexa to Epioxa.

The bear case is about concentration and profit. Growth depends heavily on iDose TR and Epioxa. The Q1 filing also showed operating expense pressure, with SG&A up 32% and R&D up 36% year over year. If sales slow before costs level off, the path to profit gets harder.

One new item is worth watching, but not treating as core yet. In February 2026, Glaukos signed an option agreement that could lead to a technology license or acquisition of a biopharmaceutical company, with up to $17.5 million in upfront payments plus future milestones. No payments had been made when the Q1 10-Q was filed.

Apr 2026→The Q1 2026 10-Q confirmed the strong quarter already reported, with net sales up 41% year over year. It also disclosed a new option agreement for a possible technology license or acquisition, but no payment had been made.

Apr 2026▲Q1 results strengthened the bull case. Net sales reached $150.6 million, iDose TR produced $54 million, and Glaukos raised 2026 net sales guidance to $620 million to $635 million.

Feb 2026→The 2025 10-K showed how dependent growth had become on iDose TR and Epioxa. It also recorded a $112.9 million Photrexa impairment and added trade policy and AI-related risks.

Feb 2026▲Glaukos said the FDA approved unlimited re-administration of iDose TR in eligible patients. Management also warned that Epioxa access would be gated until its permanent J-code became effective in July 2026.

Oct 2025▲The 10-Q confirmed FDA approval of Epioxa for keratoconus. That lowered regulatory risk for the second major growth driver after iDose TR.

Oct 2025▲Q3 2025 results showed iDose TR adoption accelerating, with about $40 million of U.S. sales. Management raised 2025 guidance and introduced a $600 million to $620 million preliminary 2026 sales outlook.

Aug 2025→The Q2 2025 10-Q confirmed strong iDose TR growth and added Mitosol through the Mobius deal. It also named transition-related sales disruption as a real risk for new products.

Jul 2025▲Q2 2025 results showed iDose TR produced about $31 million in quarterly sales. That was enough to lift U.S. Glaucoma sales 45% year over year and support a modest guidance raise.

02 Business model

Small eye markets, specialized tools

Glaukos makes money by selling products used by eye doctors and surgeons. Its main markets are glaucoma, corneal disorders, and future retinal disease programs. These are niche markets, but the products can be high value because they treat serious eye disease.

The glaucoma business includes MIGS devices, which are tiny tools used in less invasive glaucoma surgery, plus iDose TR and surgical adjuncts like Mitosol. Mitosol is an FDA-approved mitomycin-C product used to reduce scarring in glaucoma filtration surgery.

The corneal business includes Photrexa and Epioxa. Epioxa is important because it is an epi-on corneal cross-linking product, meaning the surface layer of the cornea does not need to be removed in the same way as older procedures.

The model breaks if doctors do not adopt the new products, if payers do not cover them well, or if reimbursement codes fail to make the work profitable for clinics. A permanent J-code for Epioxa became effective on July 1, 2026, which helps, but broad payer coverage still matters.

03 Product portfolio

What doctors actually use

Growth engine

iDose TR

This long-duration travoprost implant is the center of the current growth story. In Q1 2026, it produced $54 million of sales, and FDA labeling now allows unlimited re-administration in eligible patients.

Steady

iStent family

These MIGS devices built the glaucoma franchise. The legacy stent business remains a headwind in the United States, but it still gives Glaukos doctor relationships and a base to sell from.

Growth engine

Epioxa

Epioxa treats keratoconus with an epi-on cross-linking approach. Its launch began in Q1 2026, and the July 1, 2026 permanent J-code is the next test for wider use.

Cash cow

Photrexa

Photrexa is the older corneal cross-linking product. It is still producing sales during the move to Epioxa, but Glaukos recorded a $112.9 million impairment tied to the Photrexa intangible asset in 2025.

Steady

Mitosol

Mitosol came from the Mobius Therapeutics deal. It is an FDA-approved mitomycin-C formulation used to help prevent scarring in glaucoma filtration surgery.

Option

iDose TREX, iDose TRIO, and screening tools

These are pipeline programs that could extend growth beyond the first iDose TR wave. They still carry normal clinical, regulatory, and launch risk.

04 Business segments

Glaucoma is the engine

Glaucoma and related products86%growing fast

Corneal Health14%modest

The mix below uses Q1 2026 net sales of $150.6 million. Corneal Health was $21.3 million, so the remaining sales are grouped as Glaucoma and related products, including U.S. and non-U.S. glaucoma revenue.

05 Risk factors

What could go wrong

iDose TR growth slows

High impact · Medium odds

iDose TR is carrying the growth story. It generated $54 million in Q1 2026 sales, and U.S. Glaucoma grew 58% year over year. If new patient starts, repeat use, or doctor adoption slow, the company could miss the growth level investors expect.

We watchQuarterly iDose TR sales and U.S. Glaucoma growth versus the 58% Q1 2026 growth rate.

Epioxa access disappoints

High impact · Medium odds

The permanent J-code for Epioxa helps doctors bill for the product, but it does not guarantee broad payer coverage. If clinics face delays or weak payment, the Corneal Health launch could flatten after the early start.

We watchCorneal Health net sales in H2 2026 after the July 1, 2026 J-code activation.

Costs outrun sales

High impact · Medium odds

Glaukos is still unprofitable. In Q1 2026, SG&A rose 32% and R&D rose 36% year over year as the company funded launches and pipeline work. The business needs sales growth to scale faster than spending.

We watchQuarterly operating loss, cash burn, and any updated timeline to cash flow breakeven.

Legacy stents keep shrinking

Medium impact · Medium odds

The older non-iDose glaucoma business is a drag. The 2025 10-K described a single digit decline in non-iDose net sales, even as iDose TR lifted the total U.S. glaucoma franchise. If that decline deepens, iDose TR must do even more work.

We watchManagement comments on non-iDose sales and any new reimbursement limits on MIGS procedures.

Pipeline or deal risk

Medium impact · Medium odds

Future growth depends on more than the current launches. iDose TREX, iDose TRIO, screening tools, and the February 2026 option agreement could add value, but they could also fail, slip, or cost more than expected.

We watchFDA updates, trial timing, and whether Glaukos exercises the option agreement.

Valuation leaves little room

Medium impact · Medium odds

The market already gives Glaukos credit for a strong launch path. That makes the stock sensitive to even small signs of slower iDose TR growth, weaker Epioxa uptake, or delayed profitability. Good companies can still be poor stocks if the starting price is too high.

We watchRevenue guidance changes, margin progress, and the stock reaction to any launch miss.

06 Quick answers

In one breath

What does Glaukos sell?

Glaukos sells eye care devices, drug implants, and related medicines. Its main areas are glaucoma and corneal disease.

Why is iDose TR important for Glaukos?

iDose TR is the main growth driver right now. It generated $54 million in Q1 2026 sales and helped U.S. Glaucoma sales grow 58% year over year.

What is the biggest risk for GKOS stock?

The biggest risk is that launch growth slows before the company becomes profitable. Glaukos is spending heavily to support iDose TR, Epioxa, and its pipeline.

What is the Epioxa J-code and why does it matter?

A J-code is a billing code that helps doctors and clinics get paid for a drug or procedure. Epioxa's permanent J-code became effective on July 1, 2026, which should make the launch easier to scale.